Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.351, orignally discovered in South Africa and contains mutations K417N, E484K and N501Y. It also contains a C-terminal Avi-Tag and a C-terminal His-tag. The recombinant protein is>=90% pure following high affinity Ni-NTA purification and shows less than 5% aggregation in gel filtration. Constructs: Spike RBD (B.1.351) (SARS-CoV-2) (319-541-Avi-His)
Immunogen Region
319-541
Tag
C-terminal Avi-His-Tag
Formulation
8 mM phosphate pH 7.4, 110 mM NaCl, 2.2 mM KCl, 20% glycerol
Mutation
K417N, E484K, N501Y
Species
SARS-CoV-2
Application
Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling
Notes
Assay was done according to the Spike RBD (B.1.1.7 Variant) (N501Y) (SARS-CoV-2): ACE2 Inhibitor Screening Chemiluminescence Assay Kit (Biohippo #78140) with various amounts of ACE2, His-Avi-Tag, Biotinlabeled HiP (Biohippo #100665).
Avoid freeze/thaw cycles.
GenBank
MN908947
Mw(kda)
28 kDa
Synonyms
coronavirus, covid, covid-19, covid19, Sars-cov-2 B1351, 20H/501Y.V2, sars cov 2 Spike Trimer, sarscov2, South African Variant, B1351 mutation, South Africa coronavirus, SARS-CoV-2 S. African variant, 100978-1, 100978-2